CDSCO Panel Approves Pfizer Protocol Amendment proposal to study anti-cancer drug Elranatamab Dr. Divya Colin4 Nov 2024 5:45 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
CDSCO Panel Denies Pfizer Products India request for local CT waiver to market Elranatamab solution for injection Dr. Divya Colin26 Jun 2024 6:00 PM ISTNew Delhi: Noting that no new data, literature, or updates have been presented by the firm, the Subject Expert Committee (SEC) functional under the...
CDSCO panel rejects Pfizer Products India Local Clinical Trial Waiver Proposal for Elranatamab solution for injection Dr. Divya Colin27 April 2024 6:00 PM ISTNew Delhi: Reviewing the proposal presented by Pfizer Products India for grant of permission to import and market Elranatamab solution for injection...
CDSCO panel Approves Pfizer's Protocol Amendment Proposal for Anti-cancer Drug Elranatamab Dr. Divya Colin2 Jan 2024 5:30 AM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol...
Pfizer Elrexfio gets European Commission approval for Multiple Myeloma Ruchika Sharma9 Dec 2023 12:00 PM ISTThe conditional marketing authorization for ELREXFIO is valid in all 27 EU member states as well as Iceland, Liechtenstein, and Norway.
USFDA grants priority review to Pfizer Elranatamab for relapsed or refractory multiple myeloma Ruchika Sharma24 Feb 2023 2:30 PM ISTElranatamab is an investigational, off-the-shelf, humanized BCMA CD3-targeted BsAb.
Pfizer Elranatamab gets USFDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma Ruchika Sharma4 Nov 2022 3:00 PM ISTNew York: Pfizer Inc. has announced that its investigational cancer immunotherapy, elranatamab, has received Breakthrough Therapy Designation from the...
